Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience

被引：0
|
作者：
Ahmadi-Simab, K
Lamprecht, P
Hellmisch, B
Gross, WL
机构：
[1] Univ Klinikum Schleswig Holstein, Poliklin Rheumatol, D-23538 Lubeck, Germany
[2] Rheumaklin Bad Bramstedt, D-23538 Lubeck, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2004年 / 63卷 / 06期
关键词：
D O I：
10.1007/s00393-004-0594-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：495 / 497
页数：3
相关论文
共 50 条
  • [31] Treatment of pulmonary arterial hypertension with macitentan, dual endothelin receptor antagonist
    Bichara, Valentina M.
    Bevacqua, Raul J.
    INSUFICIENCIA CARDIACA, 2019, 14 (03) : 119 - 128
  • [32] Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension
    O'Callaghan, DS
    Gaine, SP
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (04) : 475 - 481
  • [33] Improvement of vascular endothelial function using the oral endothelin receptor antagonist Bosentan in patients with systemic sclerosis
    Sfikakis, P. P.
    Papamichael, C.
    Starnatelopoulos, K. S.
    Tousoulis, D.
    Fragiadaki, K. G.
    Katsichti, P.
    Stefanadis, C.
    Mavrikakis, M.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (06): : 1985 - 1993
  • [34] Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
    Hall, S. M.
    Davie, N.
    Klein, N.
    Haworth, S. G.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (04) : 851 - 860
  • [35] Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)
    Riccardi, M. T.
    Chiala, A.
    Iannone, F.
    Grattagliano, V.
    Covelli, M.
    Lapadula, G.
    REUMATISMO, 2007, 59 (02) : 135 - 139
  • [36] Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension
    Hoette, Susana
    O'Callaghan, Dermot S.
    Jardim, Carlos
    Souza, Rogerio
    JOURNAL OF RECEPTOR LIGAND AND CHANNEL RESEARCH, 2010, 3 : 113 - 121
  • [37] Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
    Kingman, Martha
    Ruggiero, Rosechelle
    Torres, Fernando
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (11) : 1847 - 1858
  • [38] Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis
    Cutolo, Maurizio
    Ruaro, Barbara
    Pizzorni, Carmen
    Ravera, Francesca
    Smith, Vanessa
    Zampogna, Giuseppe
    Paolino, Sabrina
    Seriolo, Bruno
    Cimmino, Marco
    Sulli, Alberto
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 881 - 886
  • [39] Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension
    Barst, Robyn J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (01) : 95 - 109
  • [40] Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease
    Apostolopoulou, SC
    Manginas, A
    Cokkinos, DV
    Rammos, S
    HEART, 2005, 91 (11) : 1447 - 1452
12345